 |
2005-09-27
Solvay Pharmaceuticals
to Expand Cardiology Portfolio in Asia
Seattle, WA, USA--(Jobwerx News)--Solvay Pharmaceuticals complements
Cardiology product portfolio in Asia and New Zealand with license and
supply agreement.
SOLVAY PHARMACEUTICALS and PRONOVA BIOCARE (Norway) has signed an additional
license and supply agreement for OMACOR®, a product indicated for the
secondary prevention after myocardial infarction (MI) and hypertriglyceridemia.
This agreement complements Solvay Pharmaceuticals’ Cardiology product
portfolio in Asia and New Zealand. Cardiovascular mortality and morbidity
are major causes of health concern, and increase as populations age.
Solvay Pharmaceuticals acquires the exclusive distribution rights for
India, Pakistan, Sri Lanka, Thailand, Vietnam, Singapore, Malaysia, China,
Hong-Kong and New Zealand. This is a major territorial expansion in addition
to Solvay’s current OMACOR® franchise in e.g. greater Europe and the Middle
East. Solvay Pharmaceuticals will take over the active registration in
Thailand and submit registration files for the indications secondary prevention
post-MI and hypertriglyceridemia in the other countries.
OMACOR® contains highly purified omega-3-acid ethyl esters. The product
is registered by Pronova / Solvay Pharmaceuticals in more than 30 countries
for adjuvant treatment in secondary prevention after myocardial infarction
and for treatment of increased blood triglyceride levels or hypertriglyceridemia.
OMACOR® is part of the Solvay Pharmaceuticals’ cardiology product portfolio,
which also includes the anti-hypertensives, TEVETEN® (eprosartan), PHYSIOTENS®
(moxonidine) and the lipid lowering agent LIPHANTHYL® (fenofibrate), which
was recently added to Solvay’s cardiology portfolio through the acquisition
of Fournier Pharma.
SOLVAY is an international chemical and pharmaceutical group with headquarters
in Brussels. It employs some 33,000 people (with Fournier Pharma) in 50
countries. In 2004 its consolidated pro forma sales amounted to EUR 8.5
billion generated by its three activity sectors : Chemicals, Plastics
and Pharmaceuticals.
SOLVAY PHARMACEUTICALS is the pharmaceuticals entity of Solvay. It is
a research driven pharmaceutical company that seeks to fulfill carefully
selected, unmet medical needs in the therapeutic areas of cardiology,
gastroenterology, mental health and gynecology/andrology. Solvay Pharmaceuticals
employs about 13,000 people worldwide (with Fournier Pharma).
PRONOVA BIOCARE is a world leader in Omega-3 fatty acids. The active ingredients
of OMACOR® are processed at Pronova’s plant in Sandefjord / Norway. The
production process is patented all over the world.
Click
here to view more news articles
E-mail this page to a friend 
|
|
Post
Jobs in the
Pharmaceutical Industry
 
Featured News
- GE Silicones
Chino, CA Site Achieves VPP Star Status
- American Management Association
Certification and Training Programs
- Plastics Help Medical Product
Technology Advance Rapidly
- Ticona Plastics Allows Complex
Circuit Patterns To Be Laser Etched for Hearing Aids and more
- All this Months News
Copyright - Unless
otherwise stated all
contents of this web site are © 1998/2005– JOBWERX.COM.
– All Rights Reserved. For permission to reproduce any contents of this
web site, please advise our Syndication department: Log onto HELP
Create on-line tests, quizzes,
assessments and exams in minutes!
Easy as 1, 2, 3
|
